Overview

• The drug activates signaling pathways in skeletal muscle to boost metabolism without overstimulating the heart
• A Phase I trial of 48 healthy volunteers and 25 people with type 2 diabetes showed the treatment was well tolerated
• Preclinical studies in mice and rats demonstrated improved body composition and blood sugar control without muscle loss
• Its distinct mechanism allows use as a standalone therapy or in combination with GLP-1 agonists like Ozempic
• Atrogi AB will launch a larger Phase II study to evaluate efficacy and safety in type 2 diabetes and obesity patients